Comparative Pharmacology
Head-to-head clinical analysis: KOMBIGLYZE XR versus SITAGLIPTIN AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOMBIGLYZE XR versus SITAGLIPTIN AND METFORMIN HYDROCHLORIDE.
KOMBIGLYZE XR vs SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOMBIGLYZE XR is a combination of saxagliptin, a DPP-4 inhibitor, and metformin, an AMPK activator. Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, leading to increased insulin release and decreased glucagon secretion. Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
One tablet orally once daily with food; available strengths: saxagliptin 5 mg/metformin extended-release 500 mg, saxagliptin 5 mg/metformin extended-release 1000 mg. Titrate based on glycemic response and tolerability.
Oral, initial dose based on prior therapy and glycemic control: 50 mg sitagliptin / 500 mg metformin twice daily or 50 mg sitagliptin / 1000 mg metformin twice daily. Max sitagliptin 100 mg/day, metformin 2000 mg/day.
None Documented
None Documented
Terminal elimination half-life for saxagliptin is 2.5 hours and for its active metabolite is 3.1 hours; clinical context: no significant accumulation at steady state.
Metformin: Terminal half-life ~6.2 hours (plasma), but prolonged to ~17.6 hours in renal impairment; clinical context: dosing interval adjusted for CrCl. Sitagliptin: Terminal half-life ~12.4 hours, allows once-daily dosing.
Renal excretion of unchanged saxagliptin (24%) and its active metabolite 5-hydroxy saxagliptin (22%); fecal excretion of parent (0.3%) and metabolite (6%); total renal elimination accounts for approximately 75% of the administered dose.
Metformin: 90% renal unchanged (active tubular secretion), 10% fecal. Sitagliptin: 87% renal (active tubular secretion), 13% fecal (biliary excretion minimal for sitagliptin, but fecal includes unabsorbed drug).
Category C
Category A/B
DPP-4 Inhibitor + Biguanide Combination
DPP-4 Inhibitor